Skip to main content

Table 1 Studies evaluating the efficacy of IDegLira and IGlarLixi in patients with diabetes mellitus type 2 inadequately controlled with oral medication and insulin naive

From: Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

Study DUAL-1 LixiLan-O
IDegLira Degludec Liraglutide IGlarLixi Glargine U100 Lixisenatide
Duration 26 weeks 30 weeks
Population 1663 T2DM adults, A1c 8.3 ± 0.9; BMI 31.2 ± 4.8 kg/m2, metformin ± pioglitazone 1170 T2DM adults, A1c 8.2 ± 0.7; BMI 31.7 ± 4.4 kg/m2; metformin ± pioglitazone
Mean insulin dose (final) 38 ± 13 53 ± 28   39 ± 14 40 ± 14  
ΔA1c − 1.9 ± 1.1 − 1.4 ± 1.0 − 1.3 ± 1.1 − 1.6 ± 0.1 − 1.3 ± 0.1 − 0.8 ± 0.1
Final A1c (week 30) 6.4 ± 1.0 6.9 ± 1.1 7.0 ± 1.2 6.5 ± 0.8 6.8 ± 0.8 7.3 ± 0.9
Δ body weight (kg) − 0.5 ± 3.5 + 1.6 ± 4.0 − 3.0 ± 3.5 − 0.3 ± 0.2 + 1.1 ± 0.2 − 2.3 ± 0.3
% A1c < 7% 81 65 60 74 59 33
%A1c < 7% without weight gain 46 21 54 43 25 28
%A1c < 7% without hypoglycemia 60 41 58 53 44 30
%A1c < 7% without weight gain or hypoglycemia 36 14 52 32 19 26
Hypoglycemia (%)a 32 39 7 26 24 6
  1. aDifferent definitions for hypoglycaemia were used in the two studies. For the DUAL I trial, confirmed hypoglycaemia was defined as the occurrence of episodes requiring assistance (severe), or episodes in which plasma glucose concentration (determined from self-monitored blood glucose) was less than 56 mg/dL, irrespective of symptoms. For the LixiLan-O trial, documented symptomatic hypoglycemia was defined as typical symptoms of hypoglycaemia accompanied by a measured plasma glucose concentration of #70 mg/dL